Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - methylphenidate hydrochloride, quantity: 54 mg - tablet, modified release - excipient ingredients: sodium chloride; phosphoric acid; stearic acid; iron oxide yellow; carnauba wax; povidone; polyethylene oxide; cellulose acetate; hypromellose; iron oxide black; succinic acid; butylated hydroxytoluene; poloxamer; iron oxide red; titanium dioxide; lactose monohydrate; triacetin; propylene glycol; isopropyl alcohol; purified water; macrogol 400 - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme concerta is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of concerta for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use concerta for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - methylphenidate hydrochloride, quantity: 36 mg - tablet, modified release - excipient ingredients: stearic acid; poloxamer; polyethylene oxide; butylated hydroxytoluene; iron oxide black; iron oxide yellow; phosphoric acid; cellulose acetate; hypromellose; succinic acid; carnauba wax; sodium chloride; povidone; titanium dioxide; lactose monohydrate; triacetin; macrogol 400; propylene glycol; isopropyl alcohol; purified water - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme concerta is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of concerta for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use concerta for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - methylphenidate hydrochloride, quantity: 18 mg - tablet, modified release - excipient ingredients: iron oxide yellow; sodium chloride; povidone; butylated hydroxytoluene; iron oxide black; stearic acid; polyethylene oxide; cellulose acetate; succinic acid; phosphoric acid; hypromellose; carnauba wax; poloxamer; macrogol 400; titanium dioxide; lactose monohydrate; triacetin; propylene glycol; isopropyl alcohol; purified water - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd). treatment should be commenced by a specialist.,a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.,need for comprehensive treatment programme concerta is indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational and social) for patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician?s assessment of the chronicity and severity of the patient?s symptoms.,long term use the effectiveness of concerta for long-term use has not been systematically evaluated in controlled trials. therefore the physician who elects to use concerta for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 50 mg - injection, modified release - excipient ingredients: polysorbate 20; water for injections; sodium hydroxide; dibasic sodium phosphate dihydrate; sodium chloride; citric acid; carmellose sodium - risperdal consta is indicated for the treatment of schizophrenia and related psychoses. risperdal consta is indicated for monotherapy for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in patients with a manic or mixed episode, following stabilisation with oral risperidone. adjunctive maintenance treatment with lithium or sodium valproate in treatment refractory patients with bipolar i disorder who have at least 4 relapses in a 12 month period.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 37.5 mg - injection, modified release - excipient ingredients: citric acid; sodium chloride; carmellose sodium; polysorbate 20; dibasic sodium phosphate dihydrate; sodium hydroxide; water for injections - risperdal consta is indicated for the treatment of schizophrenia and related psychoses. risperdal consta is indicated for monotherapy for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in patients with a manic or mixed episode, following stabilisation with oral risperidone. adjunctive maintenance treatment with lithium or sodium valproate in treatment refractory patients with bipolar i disorder who have at least 4 relapses in a 12 month period.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 25 mg - injection, modified release - excipient ingredients: sodium hydroxide; citric acid; sodium chloride; carmellose sodium; dibasic sodium phosphate dihydrate; polysorbate 20; water for injections - risperdal consta is indicated for the treatment of schizophrenia and related psychoses. risperdal consta is indicated for monotherapy for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar i disorder in patients with a manic or mixed episode, following stabilisation with oral risperidone. adjunctive maintenance treatment with lithium or sodium valproate in treatment refractory patients with bipolar i disorder who have at least 4 relapses in a 12 month period.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; hypromellose; propylene glycol; maize starch; sodium lauryl sulfate; magnesium stearate; purified talc; iron oxide red; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - itraconazole, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: propylene glycol; hydroxypropylbetadex; saccharin sodium; purified water; caramel; sorbitol solution (70 per cent) (non-crystallising); sodium hydroxide; hydrochloric acid; flavour - sporanox oral solution is indicated for: * the treatment of oral and/or oesophageal candidiasis in hiv-positive or other immunocompromised patients. * prophylaxis of fungal infections in neutropenic patients.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: purified water; benzoic acid; tartaric acid; sodium hydroxide - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; sunset yellow fcf; hypromellose; microcrystalline cellulose; propylene glycol; titanium dioxide; sodium lauryl sulfate; colloidal anhydrous silica; purified talc; magnesium stearate - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).